Cutaneous solution for the treatment of androgenetic alopecia 60ml

Product Description

Trefostil 5% is used in the treatment of moderate androgenetic alopecia in men.

Ingredients

Buscofenact contains: Active ingredient: 50 mg minoxidil Excipients: Propylene glycol, ethanol (96%), purified water.

Directions for use

Trefostil is a product for cutaneous use. A dose of 1 ml should be applied to the scalp, starting from the center of the affected area, twice a day. Respect the dosage regardless of the area to be treated. The total dosage should not exceed 2 ml.

Apply the product using your fingertips to the entire affected area. Wash your hands thoroughly before and after applying the solution. Before application, the hair and scalp must be completely dry. Do not apply the product to other parts of the body.

A treatment of two daily applications for a period of two months is necessary before hair growth stimulation is evident.

Contraindications

Hypersensitivity to the active substance or to any of the excipients. Scalp diseases. Poor tolerability to the 2% formulation, regardless of symptoms.

Warnings

In subjects suffering from scalp dermatoses, increased percutaneous absorption of minoxidil is possible. Although the appearance of systemic effects related to minoxidil has not been observed during use of the solution, the possibility of such effects cannot be excluded.

As a precautionary measure, the possible appearance of symptoms indicating systemic effects, such as low blood pressure, tachycardia, signs of water/sodium retention, should be regularly monitored. A medical history and clinical examination should be performed before using the medicine.

Patients with known cardiovascular disease or cardiac arrhythmias should contact a doctor before using minoxidil. In particular, they should be warned of the possible side effects and informed of the possible onset of tachycardia, fluid/sodium retention, or weight gain, or other systemic effects that require particular vigilance.

Monitoring should be performed at the beginning of treatment and regularly thereafter. Treatment should be discontinued in the event of systemic effects or severe dermatological reactions. Due to the risk of hypertrichosis in areas remote from the application site, the use of this medicine cannot be justified in women.

Minoxidil is not indicated when there is no family history of hair loss, the hair loss is sudden and/or patchy, the hair loss is due to childbirth, or the reason for the hair loss is unknown. The user should discontinue use of the product and consult a doctor if hypotension is detected or if he/she experiences chest pain, tachycardia, fainting or dizziness, sudden unexplained weight gain, swelling of the hands or feet, or persistent redness or irritation of the scalp.

Pregnancy

Systemically absorbed minoxidil is excreted in human milk. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown a risk to the fetus at exposure levels that are much higher than those intended for human exposure. A low, although remote, risk of fetal harm is possible in humans. Nevertheless, the medicine is not recommended for use in women.

Expiry

Check the expiry date indicated on the package. The expiry date indicated on the package refers to the product in its intact packaging, stored correctly. Store in the original packaging to protect the medicine from moisture. Caution: Do not use the medicine after the expiry date indicated on the package.

Format

60 ml bottle.